Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_assertion wasGeneratedBy ECO_0000203 NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_assertion wasDerivedFrom befree-20150227 NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_assertion SIO_000772 21898529 NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_assertion evidence source_evidence_literature NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.